Zhitong Finance App News and Platinum Pharmaceutical-B (02142) announced that Nona Biotech (Suzhou) Co., Ltd. (Nona Biotech), a wholly-owned subsidiary of the company, has signed an antibody-conjugated drug (ADC) discovery cooperation agreement with Boostimmune, Inc., to establish a strategic partnership for the company to develop ADC therapies. Under the agreement, Nona Biotech will supply Boostimmune with its dual and double light chain (H2L2) Harbour Miceplatform to develop ADC therapies for novel targets.
Harbour MiceThe platform can generate all-human monoclonal antibodies in double, double light chain (H2L2) and heavy chain only (HCaB) forms. Immune cell adaptor developed based on HCaB antibodies (HBICE)) It can achieve anti-tumor curative effects that cannot be achieved with traditional drug combination therapy. Harbour Mice, HBICETogether with the single B cell cloning platform, it forms a unique and efficient next-generation innovative therapeutic antibody development engine.
As Nona Biotech expands the Group's cooperation network from a global strategic perspective, this collaboration has become a milestone for the Group and also marks the industry's recognition of the Group's proprietary platform and antibody discovery capabilities. The company believes that Harbour MiceTogether with the Group's rich experience in innovative biopharmaceutical discovery, the platform can generate differentiated therapeutic molecules to benefit patients around the world.